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Abstract
Background: Lymph node status is the most important prognostic indicator in breast cancer in
recently diagnosed primary lesion. As a part of an interregional protocol using scintimammography
with Tc99m compounds, the value of planar Tc99m sestamibi scanning for axillary lymph node
evaluation is presented. Since there is a wide range of reported values, a standardized protocol of
planar imaging was performed.
Methods: One hundred and forty-nine female patients were included prospectively from different
regions. Their mean age was 55.1 ± 11.9 years. Histological report was obtained from 2.987 excised
lymph nodes from 150 axillas. An early planar chest image was obtained at 10 min in all patients
and a delayed one in 95 patients, all images performed with 740–925 MBq dose of Tc99m sestamibi.
Blind lecture of all axillary regions was interpreted by 2 independent observers considering any well
defined focal area of increased uptake as an involved axilla. Diagnostic values, 95% confidence
intervals [CI] and also likelihood ratios (LR) were calculated.
Results: Node histology demonstrated tumor involvement in 546 out of 2987 lymph nodes.
Sestamibi was positive in 30 axillas (25 true-positive) and negative in 120 (only 55 true-negative).
The sensitivity corresponded to 27.8% [CI = 18.9–38.2] and specificity to 91.7% [81.6–97.2]. The
positive and negative LR were 3.33 and 0.79, respectively. There was no difference between early
and delayed images. Sensitivity was higher in patients with palpable lesions.
Conclusion: This work confirmed that non tomographic Tc99m sestamibi scintimammography
had a very low detection rate for axillary lymph node involvement and it should not be applied for
clinical assessment of breast cancer.
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Background
Lymph node status is the most important prognostic indi-
cator in breast cancer in recently diagnosed primary
lesion. The evidence of metastatic involvement in the
axilla requires the indication of adjuvant therapy poste-
rior to surgical tumor resection. There is not an accurate
anatomical test for this purpose and clinical examination
has inappropriate diagnostic values. Routine lymph node
dissection is the only accepted method for therapeutic
decisions but it is invasive and produces significant asso-
ciated morbidity such as lymphedema and, eventually,
infections. On the other hand, an important proportion
of breast cancer patients are node-negative. Ultrasonogra-
phy has also been reported as helpful, especially adding
fine needle aspiration biopsy [1,2].
The role of nuclear techniques is controversial in the area
related with breast cancer [3,4]. Positron emission tomog-
raphy (PET) with fluorine deoxyglucose (FDG) is an excel-
lent method for breast cancer evaluation even though is
not easily available; it is used for diagnosis and surgical
planning, staging and restaging of local regional recur-
rence or distant metastases and also for monitoring ther-
apy response. Its value for detecting axillary involvement
is somehow debated and it has not been used in routine
practice in all centers, due to its current resolution for that
purpose. However, it appears to be very helpful in internal
mammary node evaluation [5-8].
Sentinel node detection with radioguided biopsy has a
well defined role in early staging of breast cancer and
small tumors. This technique allows the recognition of
lymphatic spreading. It requires nodal histology to decide
complete posterior lymphadenectomy. The strategy
involves diverse methodologies, is technically challeng-
ing, and requires a learning curve [9-12].
Scintimammography is widely available and its diagnostic
value in axillary detection is not optimal when using pla-
nar images with 99mTc-sestamibi or phosphonates. How-
ever, reports using single photon emission tomography
(SPECT) images with sestamibi and tetrofosmine labeled
with Tc99m have better figures and even pinhole SPECT
appears promising.
The aim of the present report was to evaluate through an
unbiased standardized method the diagnostic value of
planar sestamibi images for axillary involvement in breast
cancer patients. This was accomplished in the scope of a
multicenter interregional trial evaluating Tc99m com-




This prospective study included 149 female patients rang-
ing from 29 to 82 years (mean ± SD: 55,1 ± 11.9), from a
multicenter trial on scintimammography Tc99m radiop-
harmaceuticals co-ordinated by the International Atomic
Energy Agency (IAEA). Sixty per cent were postmenopau-
sal. All patients had confirmed breast carcinoma (one
patient had bilateral lesions). Only 50 patients (33.3%)
presented also with axillary palpable nodes.
Primary breast tumour histology is documented in Table
1.
The median size breast lesion was 25 mm ranging from 7
– 80 mm (mean ± SD = 28.8 ± 13.9 mm).
Scintimammography was performed before the his-
topathological confirmation of the cancer. Cases with
fine-needle aspiration as the only confirmatory procedure
were excluded. Axillary lymph node dissection in 150 axil-
lary beds was performed as a part of the standard staging.
All patients included in this group provided written
informed consent according to their local institutions at
participating centres (Chile, China, Colombia, Cuba,
Greece, India, Peru, Turkey and Uruguay).
Tc-99m scintimammography protocol
The same protocol was used in all centres. The radiochem-
ical purity of Tc-99m-MIBI was ≥95%. Patients were
injected with a bolus of 740 -925 MBq of sestamibi into
an antecubital vein in the contra-lateral arm to the breast
lesion or in a pedal vein in the patient with bilateral
lesions. A plastic cannula was used to avoid interstitial
infiltration and the injection was followed by a saline
flush.
The acquisition began 10 min post injection with the
patient supine. Imaging parameters were: matrix 256 ×
256, peak energy of 140 ± 10% KeV, high-resolution low-
Table 1: Breast tumor histology
Biopsy diagnosis Number of cases
Ductal invasive carcinoma 123
Lobular invasive carcinoma 14
Colloidal carcinoma 5
Tubular carcinoma 3
Carcinoma in situ 3
Medullary carcinoma 1
Sarcoma 1
Total 150BMC Nuclear Medicine 2005, 5:4 http://www.biomedcentral.com/1471-2385/5/4
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energy collimator. The breast-collimator distance was
kept to a minimum and a static 10 min image was always
acquired. Anterior thoracic images included the neck,
both axillas and breasts (with arms up). Lateral views were
obtained with the patients in prone position using a com-
mercially available breast pad set, (Pinestar Technology,
Inc. Greenville, PA, USA), allowing the organ to hang
freely, compressing the contra lateral breast. Delayed
images were also obtained 90 min post injection in 95
patients using the same protocol. The gamma cameras
were standard for clinical practice, including GE Starcam
o, Elscint Apex, Siemens Diacam, and Sopha Sophy.
Standardized contrasted images in gray scale were
recorded.
Data analysis
All scintimammograms were interpreted by two experi-
enced nuclear medicine physicians, blinded to clinical sta-
tus of the patients as well as to all other tests results. The
readers decided if the scan was positive or negative for
lymph node involvement in both axillas. One or more
focal areas of increased sestamibi uptake was considered
positive. Their number was also consigned. The injection
site was available for the observers only when a false pos-
itive interpretation was suspected due to radiopharmaceu-
tical retention in a lymph or venous vessel.
Lymph node histology was considered as the gold stand-
ard. Results were incorporated to Arcus Quickstat and Instat
data set for analysis.
Diagnostic values with a 95% confidence interval [CI] and
Likelihood Ratios (LR) were calculated. Student t test was
applied.
Results
One-hundred and fifty axillary lymph node dissections
were performed in the 149 patients. Malignant involve-
ment was reported in 89 out of 149 patients, (90 axillas).
A total of 2987 lymph nodes were removed with a range
of 4–47 nodes per patient (mean ± SD: 19.9 ± 9.7). Of
these 2987 nodes, 546 presented histological tumoral
status.
Sestamibi scintimammography was positive in 30 axillas
(25 of them true-positive) and negative in 120 (55 true-
negative). Thus, the sensitivity corresponded to 27.8% [CI
= 18.9–38.2] and specificity to 91.7% [CI = 81.6–97.2].
The positive and negative LR were 3.33 and 0.79,
respectively.
Two thirds of the axillas with single node involvement
were false-negative (12 cases). When multi-nodal involve-
ment was present, 31 cases with 2–5 nodes were false neg-
ative as well as 14 cases with 6–10 nodes, and in cases
with more than 11 nodes involved, 8 cases were false-neg-
ative. There was a trend to lower sensitivity in the axillas
with less than 5 nodes involved: 13.8 % versus 32.4%
(p:0.47). With the currently used cut-off of 3 nodes
involved, 53% of the false-negatives axillas were equal or
under that number.
The only five false-positives corresponded to reactive lym-
phadenitis, follicular hyperplasia or were just specified as
non-malignant.
Tc99m sestamibi performance according to axillary status Figure 1
Tc99m sestamibi performance according to axillary status.
Comparison between axillary results in early and delayed  Tc99m sestamibi in 95 patients Figure 2
Comparison between axillary results in early and delayed 
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The sensitivity of scintimammography in the group with
palpable axillary nodes was significantly higher than in
the non palpable group (p:0.036). They corresponded to
39.0% [CI = 8.8–32] versus 18.4% [CI = 24.2–55.5]. Spe-
cificities were 100% [CI = 66.4–100] versus 90,2% [CI =
78.6–92.7]; positive LR was 3.9 versus 1.87 and negative
LR 0.61 versus 0.91, respectively. See Figure 1.
There was no difference between early and delayed diag-
nostic values in the 95 patients with both exams per-
formed in identical conditions (p:0.65). See Figure 2.
Discussion
These results support that planar imaging with scinti-
mammography and Tc99m- sestamibi should be defini-
tively excluded or considered cautiously for axillary
evaluation protocols in breast cancer.
Different techniques for axillary evaluation
Yutani et al. [15] in their comparative study between FDG
PET and sestamibi-SPECT reported sensitivities of 50.0
and 37.5%, respectively, for axillary detection in 40 con-
secutive patients with head to head comparison. Their
results with tomographic images are relatively concordant
with ours. However, in this setting, theirs and our sensitiv-
ity values were disappointingly low and are clearly
opposed to several prior reports with either planar or
SPECT techniques (See Table 2; [15-28]). This could be
explained by the size and depth of the lesions, their rela-
tive low uptake and especially by the equipment resolu-
tion. Our lower detection rate compared with other
reports may be explained, in part, by the method of robust
blind reading with no interpretation bias.
It is interesting to mention that sestamibi is helpful for the
diagnosis of melanoma lymph node assessment [29],
contrary to the observed situation discussed in breast can-
cer. The reason for this fact could be the most superficial
and somehow easier to locate melanomatous involved
nodes. The nodes in axillas are deeply positioned which
can probably contribute to the lower sestamibi uptake in
breast cancer.
PET FDG has been proposed in order to reduce the pro-
portion of patients requiring axillary dissection with vari-
able results, but until now the technique cannot
adequately assess the number of nodes involved. How-
ever, it could be very helpful in the evaluation of internal
mammary chain in upper medial quadrant primary
tumours, as well as in patients with large lesions. Accord-
ing to Danforth et al. [30] in 495 patients its global sensi-
tivity for axillary involvement was 89% [95%CI = 86–92],
with a specificity of 87% [95%CI = 84–90]. Yutani et al.
[15] reported that FDG is sufficiently sensitive to rule out
lymph node metastasis. Greco et al. [5] reported in 167
patients FDG sensitivity of 94%, specificity 86% and accu-
racy of 90% for axillary evaluation.
We agree with other authors [15,23] who have published
that planar scintimammography is not recommended for
axillary evaluation. Tolmos et al. [20] do not consider the
test as reliable (they observed a kappa value of 0.49 for
interobserver agreement). Even though, there are poste-
rior and recent publications with new results still report-
ing relatively good values [17,25-28]. Limachi et al. [27]
reported lower sensitivity if fewer nodes were affected,
similar to our findings (in patients with <3 metastases,
sensitivity was 69.7%, and only one out of six patients
with a single lesion had a positive scan). See Table 3.
Other compounds labeled with Tc99m
Regarding data with other compounds labeled with
Tc99m, commonly used, especially tetrofosmin also a cat-
ionic lipophilic molecule, the values are similar to
sestamibi in breast cancer evaluation [19,31]. Akcay [19]
found comparable diagnostic value for both in a small
number of patients with involved axillary nodes. The
experience with SPECT is significantly better including
small primary breast tumours [32]. Tc99m diphospho-
nates (MDP) proposed as an interesting alternative as well
as pentavalent DMSA, have less diagnostic value than ses-
tamibi for breast primary lesions and also for axillary
node evaluation, according to our group results and oth-
ers [13,26].
Table 2: Scintimammography results according to number of axillary nodes involved
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The addition of P-SPECT
Madeddu and Spanu, using tetrofosmin, proposed
recently SPECT with pinhole (P-SPECT) as the best tech-
nique to evaluate the axilla. Their group demonstrated
that P-SPECT has better sensitivity compared to SPECT
and they, individually, were superior to planar imaging,
even for non palpable axillary lesions [33-35]. Their group
previously reported also that tetrofosmin SPECT has bet-
ter sensitivity than planar scintimammography for palpa-
ble and non palpable axillary lesions [36]. When P-SPECT
was performed with sentinel node detection both tech-
niques combined gave 100% accuracy and P-SPECT was
able to identify 81.2% of cases with a single node, and cor-
rectly classified 93.7% of the patients with ≤ or > 3 meta-
static nodes [37].
Other interesting points
It has been reported that sestamibi and FDG are related
with low radiopharmaceutical uptake in early forms of
breast carcinoma that make tumoral detection more diffi-
cult in certain cancer subtypes, such as invasive lobular
carcinoma and low-grade tumors, even with locally
advanced disease [38-40]. It appears that favorable
response to neoadjuvant therapy, in locally advanced dis-
ease is complex due to tumoral flow and metabolic
changes [41].
Finally, it should be considered that in women with a clin-
ically negative axilla the information obtained from surgi-
cal dissection in order to decide adjuvant therapy is
related to age and other factors, such as tumor characteris-
tics [42]. SPECT equipment capacity should be amelio-
rated in order to improve the detection of smaller lesions
in breast carcinoma, as was published with phantom
models [43]. The recent and excellent review by Taillefer
(44) regarding scintimammography suggested that it is
necessary to define the clinical niches of the test. In axilla,
the diagnostic accuracy of sestamibi varied between 80–
85% (with an overall accuracy of 81% (411/509) for 12
reports including two with SPECT); for him, this value is
still too low to advocate its use to avoid axillary node dis-
section in patients with proven invasive primary breast
cancer.
Conclusion
There is strong information supporting that planar sesta-
mibi data is not an adequate alternative for axillary evalu-
ation in breast cancer. We believe that countries with
limited resources regarding radiopharmaceuticals and





PET: Positron Emission Tomography
FDG: Fluorine deoxyglucose-F18
SPECT: Single Photon Emission Tomography
P-SPECT: SPECT with pinhole
Table 3: Diagnostic value of the published literature (PUBMED) in breast cancer axillary lymph node evaluation using Tc99m 
sestamibi.
Author Sensitivity (%) Specificity (%) N° of patients Ref.N°
Lam et al. Eur J Nucl Med, 1996 64 90 31 16
Cistaro et al. Minerva Chir, 1997 75 90 45 17
Schillaci et al. Anticancer Res, 1997 61.9 81 * 96.4 92.9 * 49 18
Akcay et al. Clin Nucl Med, 1997 66 100 30 19
Tolmos et al. Am Surg, 1997 75 82 31 20
Perre et al. Eur J Surg Oncol, 1997 91 64 36 21
Taillefer et al. J Nucl Med, 1998 79.2 84.6 100 22
Danielsson et al. Acta Radiol, 1999 67 80 58 23
Arslan et al. Nucl Med Commun, 1999 68 93 77 24
Mulero et al. Rev Esp Med Nucl, 2000 36 100 84 25
Yutani et al. J Comput Assist Tomography, 2000 38* NA 40 15
Nishiyama et al. Eur J Nucl Med, 2001 73 NA 50 26
Lumachi et al. Eur J Surg Oncol, 2001 82.3 94.1 239 27
Chen et al. Chin Med J, 2003 83.3 86.1 60 28
IAEA group 28 92 149
NA : Not available
* : SPECTBMC Nuclear Medicine 2005, 5:4 http://www.biomedcentral.com/1471-2385/5/4
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